Sanofi (NASDAQ:SNY) Shares Purchased by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. boosted its position in Sanofi (NASDAQ:SNY – Get Rating) by 6.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,250 shares of the company’s stock after acquiring an additional 978 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Sanofi were worth $580,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Fairfield Bush & CO. acquired a new stake in Sanofi in the first quarter valued at approximately $26,000. Eagle Bay Advisors LLC purchased a new position in Sanofi in the second quarter valued at approximately $28,000. Ronald Blue Trust Inc. purchased a new position in Sanofi in the second quarter valued at approximately $34,000. Destiny Wealth Partners LLC increased its stake in Sanofi by 162.0% in the second quarter. Destiny Wealth Partners LLC now owns 676 shares of the company’s stock valued at $34,000 after purchasing an additional 418 shares during the last quarter. Finally, Bogart Wealth LLC increased its stake in Sanofi by 740.7% in the second quarter. Bogart Wealth LLC now owns 681 shares of the company’s stock valued at $34,000 after purchasing an additional 600 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $49.27 on Tuesday. The firm’s fifty day moving average price is $46.54 and its 200 day moving average price is $42.38. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The firm has a market cap of $124.90 billion, a price-to-earnings ratio of 17.85, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56.

Sanofi (NASDAQ:SNY – Get Rating) last posted its quarterly earnings data on Friday, October 28th. The company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.13. Sanofi had a net margin of 15.10% and a return on equity of 27.03%. The firm had revenue of $12.58 billion for the quarter, compared to analyst estimates of $12.05 billion. On average, sell-side analysts expect that Sanofi will post 4.32 EPS for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several recent analyst reports. StockNews.com initiated coverage on shares of Sanofi in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, December 16th. They set a “buy” rating on the stock. Barclays lowered their target price on shares of Sanofi from €105.00 ($114.13) to €85.00 ($92.39) and set an “equal weight” rating on the stock in a research report on Friday, October 14th. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, December 2nd. Finally, Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research report on Tuesday, December 13th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.

About Sanofi

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.